CPRIT Announces Funding

Aug 31, 2021, 17:53 PM by Melodi Moore

CPRIT announced on August 31, the release of four (4) RFAs for the Academic Research program.  Complete RFAs and instructions detailing applicable deadlines and requirements are available in the Apply for Funding section of CPRIT’s website.  The application receipt dates from CPRIT are October 13, 2021 - January 12, 2022.  Because of the institutional limitations, UTMB will not allow submissions until after October 25, 2021

 

Clinical Trials Network Award (CTNA)

The Clinical Trials Network Award (CTNA) will be made to Lead Institutions (LI) to develop and oversee a network of two cancer care facilities (Network Affiliates) (Stage 1) to extend access to a select group of LI cancer clinical trials. Once an initial network is satisfactorily demonstrated, the LI will be eligible to receive additional CPRIT funding to expand its network to two additional facilities that must be located outside the LI current catchment area (Stage 2).

Award: Up to $600,000 annually for stage 1 and up to $900,000, annually for stage 2. Maximum duration: 4 years

Core Facility Support Awards (CFSA) (Limit 1 proposal per institution)

Solicits applications from institutions to establish or enhance core facilities (laboratory, clinical, population-based, or computer-based) that will directly support cancer research programs to advance knowledge of the causes, prevention, and/or treatment of cancer or improve quality of life for cancer patients during or after treatment.

Award: Up to $4,000,000 (total costs); Maximum duration: 5 years.

Early Clinical Investigator Award (ECI) (Limit 2 proposals per institution)

Solicits applications from institutions to provide cancer physicians early in their academic career the opportunity to develop clinical research skills and to gain experience in advanced methods and experimental approaches needed to become clinical investigators; to provide an opportunity to establish a partnership with a laboratory-based collaborator in order to design and conduct correlative studies needed to interpret the outcome of an interventional trial; to provide the protected time from clinical responsibilities required to develop and conduct investigator initiated clinical trials; and to increase the pool of clinical investigators at Texas academic institutions who are conducting patient-oriented studies, capitalizing on basic discoveries and translating them through conduct of innovative clinical trials involving cancer patients or individuals at risk for cancer.

Award: Up to $1,5000,000 (total costs) Maximum duration: 5 years

High-Impact/High-Risk Research Awards (HIHR) (Limit 5 proposals per institution)

Provides short-term funding to explore the feasibility of high-risk projects that, if successful, would contribute major new insights into the etiology, diagnosis, treatment, or prevention of cancers.

Award: Up to $250,000 (total costs); Maximum duration: 2 years.


PLEASE NOTE:  Three (3) of these have institutional limits.  Those wishing to apply for them will need to follow the UTMB Limited Submission policy.

Submit by email the following documentation to Melodi MooreResearch Services Research Development Specialist (mdmoore@utmb.edu) by 5:00 pm October 13. Please put "PI last name_CPRIT_Name of Award" in the subject line.

Grant Proposal (two-page maximum) to include:

  • Title of project
  • PI name, title, department, institution, email (and cooperating institutions if called for)
  • Abstract of up to 800 words
  • Timeline including milestones for the funding period

Biosketch for the PI (not included in two-page limit)

Brief list of relevant cited literature  (not included in two-page limit)

All competitive applications will be reviewed and applicants will be notified of acceptance and rejection no later than COB, October 25, 2021.  If the institutional limit is not reached, applicants will be notified to submit applications before this date.